Cargando…

Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials

INTRODUCTION: Recent large clinical trials have yielded disappointing results of rosuvastatin in the chronic heart failure (CHF) population. The question that remains is whether these results of rosuvastatin studies could be extended to other statins. Therefore, we performed a meta-analysis based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Minwen, Yuan, Gaohui, Wei, Fanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302697/
https://www.ncbi.nlm.nih.gov/pubmed/22427759
http://dx.doi.org/10.5114/aoms.2010.19293
_version_ 1782226658453880832
author Xu, Minwen
Yuan, Gaohui
Wei, Fanping
author_facet Xu, Minwen
Yuan, Gaohui
Wei, Fanping
author_sort Xu, Minwen
collection PubMed
description INTRODUCTION: Recent large clinical trials have yielded disappointing results of rosuvastatin in the chronic heart failure (CHF) population. The question that remains is whether these results of rosuvastatin studies could be extended to other statins. Therefore, we performed a meta-analysis based on all currently available randomized controlled trials (RCTs) to evaluate the clinical efficacy of atorvastatin in CHF patients. MATERIAL AND METHODS: The published literature was scanned by formal searches of electronic databases up to January 2010. RCTs were eligible for inclusion if they compared atorvastatin versus placebo treatment in patients with CHF and reported the clinical outcomes. RESULTS: Pre-specified criteria were met by 7 trials involving 540 patients. The primary endpoint, all-cause mortality, was significantly reduced with atorvastatin therapy compared with placebo in CHF patients (odds ratio [OR] 0.39, P = 0.002), with similar results in cardiovascular mortality (OR 0.28, P = 0.002) and sudden cardiac death (OR 0.24, P = 0.01). There was also a significant decrease in hospitalization for worsening CHF with atorvastatin therapy compared with placebo (OR 0.30, P < 0.001). CONCLUSIONS: This meta-analysis suggests the effectiveness of atorvastatin treatment in reducing the risks of all-cause mortality and worsening CHF hospitalization in patients with CHF. Further large, well-conducted randomized trials are needed to confirm the benefits of atorvastatin or other statins for CHF relative to placebo or rosuvastatin.
format Online
Article
Text
id pubmed-3302697
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-33026972012-03-16 Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials Xu, Minwen Yuan, Gaohui Wei, Fanping Arch Med Sci Clinical Research INTRODUCTION: Recent large clinical trials have yielded disappointing results of rosuvastatin in the chronic heart failure (CHF) population. The question that remains is whether these results of rosuvastatin studies could be extended to other statins. Therefore, we performed a meta-analysis based on all currently available randomized controlled trials (RCTs) to evaluate the clinical efficacy of atorvastatin in CHF patients. MATERIAL AND METHODS: The published literature was scanned by formal searches of electronic databases up to January 2010. RCTs were eligible for inclusion if they compared atorvastatin versus placebo treatment in patients with CHF and reported the clinical outcomes. RESULTS: Pre-specified criteria were met by 7 trials involving 540 patients. The primary endpoint, all-cause mortality, was significantly reduced with atorvastatin therapy compared with placebo in CHF patients (odds ratio [OR] 0.39, P = 0.002), with similar results in cardiovascular mortality (OR 0.28, P = 0.002) and sudden cardiac death (OR 0.24, P = 0.01). There was also a significant decrease in hospitalization for worsening CHF with atorvastatin therapy compared with placebo (OR 0.30, P < 0.001). CONCLUSIONS: This meta-analysis suggests the effectiveness of atorvastatin treatment in reducing the risks of all-cause mortality and worsening CHF hospitalization in patients with CHF. Further large, well-conducted randomized trials are needed to confirm the benefits of atorvastatin or other statins for CHF relative to placebo or rosuvastatin. Termedia Publishing House 2010-12 2010-12-29 /pmc/articles/PMC3302697/ /pubmed/22427759 http://dx.doi.org/10.5114/aoms.2010.19293 Text en Copyright © 2010 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Xu, Minwen
Yuan, Gaohui
Wei, Fanping
Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title_full Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title_fullStr Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title_full_unstemmed Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title_short Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
title_sort effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302697/
https://www.ncbi.nlm.nih.gov/pubmed/22427759
http://dx.doi.org/10.5114/aoms.2010.19293
work_keys_str_mv AT xuminwen effectofatorvastatininpatientswithchronicheartfailureinsightsfromrandomizedclinicaltrials
AT yuangaohui effectofatorvastatininpatientswithchronicheartfailureinsightsfromrandomizedclinicaltrials
AT weifanping effectofatorvastatininpatientswithchronicheartfailureinsightsfromrandomizedclinicaltrials